This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos. For additional information please visit Newshome.
New Pradaxa® data to be presented during the American College of Cardiology’s 63rd Annual Scientific Session
10,000 patients with atrial fibrillation now enrolled in innovative GLORIA™-AF Registry
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
New data on safety and efficacy of Pradaxa® in treatment of acute deep vein thrombosis and pulmonary embolism
New data analyses show consistent efficacy and safety profile of Pradaxa® in broad range of patients with acute deep vein thrombosis or pulmonary embolism*
Preventing AF related strokes is vital. Protecting your brain protects your world.